



NP & PA Prescribing Of Buprenorphine For TennCare Members

Office-Based Opioid Treatment Facility (OBOTs)

August 31, 2020

Agenda

1. Overview of the NP PA Prescribing of Buprenorphine for TennCare members
2. Provider Initiation of Contracting
3. Question & Answers

Agenda

1. Overview of the NP PA Prescribing of Buprenorphine for TennCare members
2. Provider Initiation of Contracting
3. Question & Answers



State of Tennessee

PUBLIC CHAPTER NO. 771

HOUSE BILL NO. 1980

By Representatives Vaughan, Faison, Matthew Hill, Dunn, White, Hurt, Helton, Smith, Sherrell, Hardaway

Substituted for: Senate Bill No. 1938

By Senators Briggs, Jackson

AN ACT to amend Tennessee Code Annotated, Title 53, Chapter 11, relative to drugs.

BE IT ENACTED BY THE GENERAL ASSEMBLY OF THE STATE OF TENNESSEE:

SECTION 1. Tennessee Code Annotated, Section 53-11-311, is amended by adding the following as a new subsection:

(1) Notwithstanding subsection (c), this subsection controls the prescription of buprenorphine products by any healthcare provider licensed under title 63, chapter 7 or 19, who is employed by or contracted with a nonresidential office-based opiate treatment facility, as defined in § 33-2-402.

(2) A healthcare provider licensed under title 63, chapter 7 or 19, may prescribe a buprenorphine product, as approved by the federal food and drug administration for use in recovery or medication-assisted treatment if:

(A) The provider works in a nonresidential office-based opiate treatment facility, as defined in § 33-2-402, that is licensed by the department of mental health and substance abuse services and that does not have authority to dispense buprenorphine products;

(B) The provider practices under the direct supervision of a physician who is licensed under title 63, chapter 6 or chapter 9; holds an active Drug Addiction Treatment Act of 2000 (DATA 2000) waiver from the United States drug enforcement administration; and is actively treating patients with buprenorphine products for recovery or medication-assisted treatment at the same nonresidential office-based opiate treatment facility, as defined in § 33-2-402, as the provider;

(C) The facility and its healthcare providers are contracted and credentialed with TennCare and TennCare's managed care organizations to treat opioid use disorder with buprenorphine products for use in recovery or medication-assisted treatment;

(D) The facility or its healthcare providers are directly billing TennCare and TennCare's managed care organizations for the services provided within the facility;

Nurse Practitioners (NPs) and Physician Assistants (PAs) are now authorized to prescribe buprenorphine to TennCare members if certain conditions are met

PC 771 dictates the regulations for NPs and PAs prescribing buprenorphine in a nonresidential office-based opiate treatment (OBOT) facility (as defined in T.C.A. § 33-2-402).

Buprenorphine Prescribing for TennCare Members (1/2)

1. The NP or PA has an active Medicaid ID assigned by TennCare.
2. The NP or PA has an active DATA 2000 Waiver
3. The NP or PA has a supervising physician with an active DATA 2000 Waiver
4. Specialized in family, adult, or psychiatric medicine

Buprenorphine Prescribing for TennCare Members (2/2)

5. The NP or PA is contracted into the MCO's enhanced buprenorphine MAT Provider Network. This Network will now be known as the *Buprenorphine Enhanced Supportive Medication-Assisted Recovery and Treatment (BE-SMART) Network*. All NPs and PAs are knowingly subject to the requirements outlined in the associated MAT Network Program Description.
6. The NP or PA attests to the most recent BE-SMART Program Description as approved by TennCare and the MCO.
7. The NP or PA has a supervising physician that is contracted within the MCO's BE-SMART Network.

PC771 Regulations

The MCOs are required to confirm and record the following for all NPs and PAs that choose to contract with the MCO to treat members with buprenorphine for Medication Assisted Treatment (MAT):

1. The **supervising physician does not exceed the limit for number of buprenorphine-prescribing NPs and PAs** that can report to him or her:
 - For OBOTs, the supervising physician can oversee a *total* of two (2) NPs and PAs.
2. The NP or PA does **not exceed their individual patient prescription limit** as set forth by the legislation
 - For OBOTs, an NP or PA can only write buprenorphine prescriptions for 100 or fewer patients at a given time.

Important Note

It is up to each MCO to determine which providers to contract with for the MAT Provider Network

Contracting is NOT guaranteed

Agenda

1. Overview of the NP PA Prescribing of Buprenorphine for TennCare members

2. Provider Initiation of Contracting

3. Question & Answers

TennCare's Opioid Strategy

Primary Prevention
limit opioid exposure to prevent progression to chronic opioid use

Non-Chronic and First Time Users of Opioids

- Implemented rule in January 2018 placing dosage and day coverage allowances on opioid prescriptions for naïve and acute users.
- Increased prior authorization requirements for all opioid refills.
- Continued support of nonpharmacological pain management and clinical services, such as physical therapy.

Secondary Prevention
early detection and intervention to reduce impact of opioid misuse

Women of Childbearing Age & Provider Education

- Partnering with Tennessee Department of Health to better integrate the Controlled Substance Monitoring Database (CSMD).
- Developed MCO strategy to proactively engage women of childbearing age using opioids based on data and clinical risk.
 - The MCOs have performed thousands of outreaches to women of childbearing age over the past year. This is an ongoing effort by all MCOs.

Tertiary Prevention
support active recovery for severe opioid dependence and addiction

Chronic Dependent and Addicted Users

- Increased outreach to chronic opioid users to refer to treatment and prevent overdoses.
- The MCOs are actively building their networks of medication assisted treatment (MAT) provider to broaden access to high quality treatment for opioid and substance use disorder.
- Aligned chronic opioid user MME dosage allowances with CDC chronic pain guidelines.



The MAT Network: Support active recovery for severe opioid dependence and addiction

Buprenorphine Program Description

Buprenorphine Medication Assisted Treatment (MAT) Program Description
Division of TennCare

Overview of the Opioid Use Disorder Medication Assisted Treatment Program

The Division of TennCare along with the contracted Managed Care Organizations (MCO), Amerigroup, BlueCare and United Healthcare, has determined the need for a comprehensive network of providers who offer specific treatment for members with opioid use disorder (OUD). These providers may be agencies or licensed independent practitioners, but all must attest to provide treatment as outlined in this program description to be included in this network.

Medication Assisted Treatment (MAT) for persons diagnosed with opioid-use disorder is the use of medications, in combination with counseling and behavioral therapies, to provide a whole-patient approach to the treatment of substance use disorders. Research shows that when treating substance-use disorders, a combination of medication and behavioral therapies is most successful. The duration of treatment should be based on the needs of the persons served. The Food and Drug Administration (FDA) has approved several medications for the use in treatment of opioid-use disorder which include buprenorphine containing products and naltrexone products.

Treatment with buprenorphine for opioid use disorders is considered an evidence-based best practice by the Substance Abuse and Mental Health Services Administration (SAMHSA) Center and the American Society of Addiction Medicine (ASAM) for substance abuse treatment. **This Buprenorphine MAT Program Description outlines treatment and clinical care activities expected of providers who prescribe buprenorphine products and professionals who provide therapy, care coordination or other ancillary services for those members who are being treated with buprenorphine products.** For providers who prescribe naltrexone based products, refer to Naltrexone MAT Program Description

Naltrexone Program Description

Naltrexone Medication Assisted Treatment (MAT) Program Description
Division of TennCare


Overview of the Opioid Use Disorder Medication Assisted Treatment Program

The Division of TennCare along with the contracted Managed Care Organizations (Amerigroup, BlueCare and United Healthcare) has determined the need for a comprehensive network of providers who offer specific treatment for members with opioid use disorder. These providers may be agencies or licensed independent practitioners, but all must attest to provide treatment as outlined in this program description to be included in this network.

Medication Assisted Treatment (MAT) for persons diagnosed with opioid-use disorder is the use of medications, in combination with counseling and behavioral therapies, to provide a whole-patient approach to the treatment of substance use disorders. Research shows that when treating substance-use disorders, a combination of medication and behavioral therapies is most successful. The duration of treatment should be based on the needs of the persons served. The Food and Drug Administration (FDA) has approved several medications for the use in treatment of opioid-use disorder (OUD) which include buprenorphine containing products and naltrexone products

Treatment with buprenorphine and naltrexone for opioid use disorders is considered an evidence-based best practice by the Substance Abuse and Mental Health Services Administration (SAMHSA) Center and the American Society of Addiction Medicine (ASAM) for substance abuse treatment. **This naltrexone MAT Program Description outlines treatment and clinical care activities expected of providers who prescribe naltrexone products and professionals who provide therapy, care coordination or other ancillary services for those members who are being treated with naltrexone products.** For providers who prescribe buprenorphine based products, refer to Buprenorphine MAT Program Description.

The high-quality, specialized MAT Provider Network launched January 1, 2019



There are currently **180** newly contracted MAT providers and the number is continuing to increase.

MAT Program Description: Overview

- ❖ The Buprenorphine MAT Program Description is the **same for all three MCOs** (BlueCare, Amerigroup and United Healthcare)
- ❖ The Program Description was developed **based on national guidelines** (i.e. ASAM, SAMHSA) and is in line with State of Tennessee OBOT guidelines
- ❖ Please locate the Program Description on TennCare's Opioid Strategy Page:
<https://www.tn.gov/tenncare/tenncare-s-opioid-strategy.html>

Buprenorphine Medication Assisted Treatment (MAT) Program Description Division of TennCare

Overview of the Opioid Use Disorder Medication Assisted Treatment Program

The Division of TennCare along with the contracted Managed Care Organizations (Amerigroup, BlueCare and United Healthcare) has determined the need for a comprehensive network of providers who offer specific treatment for members with opioid use disorder. These providers may be agencies or licensed independent practitioners, but all must attest to provide treatment as outlined in this program description to be included in this network.

Medication Assisted Treatment (MAT) for persons diagnosed with opioid-use disorder is the use of medications, in combination with counseling and behavioral therapies, to provide a whole-patient approach to the treatment of substance use disorders. Research shows that when treating substance-use disorders, a combination of medication and behavioral therapies is most successful. The duration of treatment should be based on the needs of the persons served. The Food and Drug Administration (FDA) has approved several medications for the use in treatment of opioid-use disorder which include buprenorphine containing products and naltrexone products

Treatment with buprenorphine for opioid use disorders is considered an evidence-based best practice by the Substance Abuse and Mental Health Services Administration (SAMHSA) Center and the American Society of Addiction Medicine (ASAM) for substance abuse treatment. This Buprenorphine MAT Program Description outlines treatment and clinical care activities expected of providers who prescribe buprenorphine products and professionals who provide therapy, care coordination or other ancillary services for those members who are being treated with buprenorphine products. For providers who prescribe naltrexone based products, refer to Naltrexone MAT Program Description

Treatment Elements


The required treatment elements for providers rendering Medication Assisted Treatment using buprenorphine are as follows:

- The preferred medication would be the buprenorphine/naloxone combination (as covered by the TennCare formulary) for induction as well as stabilization unless contraindicated (e.g. pregnancy) and then the buprenorphine monotherapy is recommended. The buprenorphine/naloxone combination serves to minimize diversion and intravenous abuse.

UHCCP MAT Program Description V1 4.17.18

What does a “Contracted MAT Provider” mean?

Contracted with TennCare MCO



To be a contracted buprenorphine MAT provider, a provider **must**:

- Have a Medicaid ID
- **Review and provide all services** outlined in the program description requirements
- **Attest** to the MAT program description for *each MCO they contract with*
- **Contract** with each individual MCO they choose

What will I have to do as a provider to join the network?

1

Understand program description and evaluate your current care model

2

Identify any potential gaps or areas for increased support from MCOs

3

Obtain Medicaid Provider ID if needed

4

Indicate interest in joining the MAT network and ability to meet program standard

5

Contract/Re-Contract as a MAT provider with appropriate MCO(s) to join network*

6

Continue to provide high quality MAT care to TennCare members

Complete Provider Interest Form

If you are interested in receiving more information or participating in this network, please click the link below to complete the *Provider Interest Form*.

**Completing this form does NOT guarantee contracting with the Managed Care Organizations.*

Direct link to Provider Interest Form: <https://stateofennessee.formstack.com/forms/bmatp>

Division of TennCare
Buprenorphine Medication Assisted Treatment (MAT) Program:
Provider Interest Form – including Nurse Practitioners and Physician Assistants

The Division of TennCare along with the contracted Managed Care Organizations (MCOs)–Amerigroup, BlueCare and United Healthcare– have developed an enhanced network of buprenorphine providers who offer specific treatment for members with opioid use disorder (OUD), currently known as our MAT Provider Network.

In response to the recent legislation passed by the Tennessee General Assembly (PC 771 and PC 761), Nurse Practitioners (NPs) and Physician Assistants (PAs) specializing in family, adult, or psychiatric medicine are now authorized to prescribe buprenorphine with a Drug Addiction Treatment Act of 2000 (DATA 2000) waiver if certain conditions are met.

All providers that are contracted by the MCO to prescribe buprenorphine in the MAT Provider Network must attest to provide treatment as outlined in the Program Description (located on the *TennCare Opioid Strategy Website*) to be included in this network.

Please complete the following *Provider Interest Form* if you are interested in potentially contracting with an MCO to be in the MAT Provider Network.

Completing this form does NOT guarantee contracting with the Managed Care Organizations. For questions about contracting, please contact the Managed Care Organizations.

What is your provider type? *

- MD/DO
- NP
- PA

[Submit Form](#)

Note: Please select if you are a Nurse Practitioner, Physician’s Assistant, or Physician

Survey will take less than 5 minutes to complete



The Provider Interest Form is located on the TennCare Opioid Strategy webpage: <https://www.tn.gov/tenncare/tenncare-s-opioid-strategy.html>

The Webinar will be posted on TennCare's Website

Link to Webpage with Webinar:

<https://www.tn.gov/tenncare/tenncare-s-opioid-strategy.html>

**Webinar will be posted as a separate link on the Opioid Strategy page*

For more information or questions, please refer to the contacts below:

	Contact Name	MAT Contact Information
TennCare	Mary Shelton Director of Behavioral Health Services	Mary.c.shelton@tn.gov
BlueCare	Melissa Isbell Manager, Behavioral Health Network Strategy and Innovation	MAT_Referral_CM_UM@bcbst.com (copy melissa_isbell@bcbst.com)
Amerigroup	Internal Provider Relations Team	(615) 232-2160
United Healthcare	Provider Customer Service	(800) 690-1606

Agenda

1. Overview of the NP PA Prescribing of Buprenorphine for TennCare members
2. Provider Initiation of Contracting
3. Question & Answers

Questions

Please submit all questions through
the chat feature to the Host &
Panelists



Thank you!